Vyne Therapeutics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
VYNE Therapeutics Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, auditor ratification, and executive compensation, while revealing increasing net losses and a recent Phase 2b trial failure.
NASDAQ
VYNE Therapeutics is holding its annual meeting on December 12, 2024, to vote on key proposals including the election of directors, ratification of the auditor, executive compensation, and an amendment to the equity incentive plan.